Phagolysosome

A **phagolysosome** is a hybrid organelle resulting from the fusion of a phagosome (which contains ingested particles like microbes, apoptotic cells, or debris) with a lysosome (which provides degradative enzymes)[1][2][3][4][5][7]. This process occurs in both professional (e.g., macrophages, neutrophils, dendritic cells) and non-professional phagocytic cells. The phagolysosome provides a highly acidic, hydrolytic, and sometimes oxidative environment, enabling the breakdown and neutralization of its contents, which is essential for immune defense and tissue homeostasis[1][4][5][7]. Phagolysosome maturation involves a drop in pH (to as low as 4-5), activation of hydrolytic enzymes, and sometimes the generation of reactive oxygen species and other antimicrobial agents[1][5][3]. Impaired phagolysosome formation or function contributes to increased susceptibility to infection and can influence inflammatory and other disease states[5]. The term *phagolysosome* describes a cellular compartment, not a protein, receptor, or conventional drug target. Additional notes: - **is_incorrect:** This entry is *not* a conventional druggable target such as a receptor, enzyme, transporter, or signaling protein. Rather, it describes a *subcellular organelle* involved in immune response and cellular clearance processes. It is not the direct molecular target of current drugs or biomarker assays[1][5][7]. - Phagolysosome formation may be exploited or blocked by pathogens (such as *Mycobacterium tuberculosis*, *Leishmania*, etc.), but drugs do not directly bind or target "phagolysosome" as an entity—instead, they may act on pathways or proteins regulating its formation or function[5]. - No standardized abbreviation is commonly used; both "phagolysosome" and "endolysosome" refer to the organelle[1]. This concept should be excluded from structured molecular target databases, as it is not a canonical molecular target, receptor, or druggable entity.

Other names

Endolysosome